Budget 2022-23 is likely to improve research and innovation in the pharma sector

Know more→

Mobility Energy and Transportation

Healthcare and Lifesciences

Budget 2022-23 is likely to improve research and innovation in the pharma sector

02 Feb 2022

1 min read

Pointing out that the incentives in the budget will further improve innovation in healthcare, Richa Mahindru, Domain Leader, Pharma and Life Sciences, Praxis Global Alliance said, “The Union Budget 2022 is predictably aligned for the Pharma and Healthcare sector in continuation to the previously announced production linked incentives and policies under Aatma Nirbhar Bharat Abhiyaan scheme. The budget will provide improved access for mental health counseling and healthcare facilities with the launch of the National Tele Mental Health program. With a stepped-up expenditure allocation of 137 percent in the Healthcare industry and PLIs in place for domestic manufacturing of APIs, KSMs, and drug intermediates, the budget is poised to support the innovation of new drugs and provide affordable access to healthcare facilities."

Click here to read the full article on ET Healthworld

Disclaimer: The text, images and content here have been reproduced from the original publisher. Praxian Global Private Limited does not claim any ownership or right to use of this content and the rights belong to the publisher. We have contributed our perspectives, which are often proprietary, to the content publisher. We or the publisher have no obligation to update or refresh the content or our perspectives shared herein.

Ready to talk?

I want to talk to your experts in:

We work with ambitious leaders and transformative clients who are defining the future. Together, we achieve extraordinary outcomes.

Budget 2022-23 is likely to improve research and innovation in the pharma sector | PraxisGA